Monday, November 16, 2026 Never miss a recall or a rule change Get the free brief →
Inside MedSpa
FDA Recall & Compliance Alerts for Medspa Owners
Business & M&AInMode Q3 revenue holds near $92.1M, margins slip3 days agoRegulatoryJudge bars Medicare price for Botox over plasma rulelast weekRegulatoryMexico approves Restylane Shaype for jawline first3 days agoBusiness & M&AEvolus posts Q3 loss of $0.09, revenue tops estimateslast weekBusiness & M&ACoty shareholders approve 50M-share equity plan boost4 days agoMarketAllergan posts nine ASDS abstracts, two on GLP-1 patientslast weekDevices & TechConexeu's first human collagen batch meets its own specs5 days agoBusiness & M&AGalderma lifts 2026 sales outlook to 22.5-23.5%last weekBusiness & M&AMedytox Q3 operating profit up 74.5% on toxin sales5 days agoBusiness & M&ACytrellis Brings ellacor into UM Nurse Practitioner Courselast weekRegulatoryTrifluent recalls Tridacaine III lidocaine patch6 days agoRegulatoryFDA clears Shenzhen Bway red/NIR LED face mask6 days ago
Regulatory

Regulatory

The latest in regulatory for medical-aesthetics practice owners.

Mexico approves Restylane Shaype for jawline first Regulatory

Mexico approves Restylane Shaype for jawline first

Galderma's firmer HA gel now has a Mexican approval for jawline definition, the first anywhere in the world for that area.

Nov 13, 2026
Trifluent recalls Tridacaine III lidocaine patch Regulatory

Trifluent recalls Tridacaine III lidocaine patch

The FDA recall list names Trifluent Pharma's Tridacaine III Lidocaine Patch 5%, but the listing excerpt gives almost no detail on why.

Nov 10, 2026
FDA clears Shenzhen Bway red/NIR LED face mask Regulatory

FDA clears Shenzhen Bway red/NIR LED face mask

A China-based applicant won a 510(k) for eight LED face mask models sold as over-the-counter wrinkle reduction devices.

Nov 10, 2026
Judge bars Medicare price for Botox over plasma rule Regulatory

Judge bars Medicare price for Botox over plasma rule

A D.C. federal judge ruled Botox should have been excluded from Medicare's third negotiation round, and HHS has not said whether it will appeal.

Nov 7, 2026
FDA clears AMIRO LED wrinkle mask under 510(k) Regulatory

FDA clears AMIRO LED wrinkle mask under 510(k)

Shenzhen Accompany Technology's over-the-counter light mask was found substantially equivalent to a predicate, and the FDA listing says little more.

Nov 3, 2026
Inibio's Inibo wins China approval, third Korean toxin Regulatory

Inibio's Inibo wins China approval, third Korean toxin

China's NMPA has approved Inibio's type-A botulinum toxin, with commercial launch targeted for Q1 2027.

Oct 31, 2026
Galderma's Relfydess Approved in China for Frown Lines Regulatory

Galderma's Relfydess Approved in China for Frown Lines

China's NMPA has approved Relfydess, a ready-to-use liquid neuromodulator, for moderate-to-severe glabellar lines, marking Galderma's entry into one of the world's largest aesthetics markets.

Oct 26, 2026
Sisram's Profhilo clears China regulatory hurdle Regulatory

Sisram's Profhilo clears China regulatory hurdle

The Hong Kong-listed company's hyaluronate injectable has won NMPA acceptance for its facial indication, setting up a China launch.

Oct 20, 2026
Allergan gets Health Canada nod for Boey, a fast-acting short-duration toxin Regulatory

Allergan gets Health Canada nod for Boey, a fast-acting short-duration toxin

Boey (trenibotulinumtoxinE) is authorized in Canada for glabellar lines and works in hours instead of days, with effects lasting two to three weeks.

Sep 30, 2026
Indiana Tightens Medical Spa Regulations Under Public Law 136 Regulatory

Indiana Tightens Medical Spa Regulations Under Public Law 136

New state law raises licensing and supervision requirements, affecting independent medspa operations and staffing models.

Jul 29, 2026
AbbVie Sues Galderma Over Patented Dermal Filler Syringe Designs Regulatory

AbbVie Sues Galderma Over Patented Dermal Filler Syringe Designs

Patent litigation over syringe technology could affect filler supply and pricing dynamics.

Jul 25, 2026
Medicare Adds Botox to Price-Negotiation List — What Payers Negotiating Toxin Costs Means for Your Reimbursement Regulatory

Medicare Adds Botox to Price-Negotiation List — What Payers Negotiating Toxin Costs Means for Your Reimbursement

CMS includes Botox among 15 drugs eligible for Medicare price negotiation in 2026, signaling payer focus on high-volume, high-cost injectables.

Jul 15, 2026
Galderma's Relfydess Botox Rival Hits FDA Roadblock — What Practices Need to Know Regulatory

Galderma's Relfydess Botox Rival Hits FDA Roadblock — What Practices Need to Know

The FDA issued a Complete Response Letter for RelabotulinumtoxinA, delaying Galderma's entry into the U.S. neuromodulator market.

Jul 7, 2026
Galderma Receives Complete Response Letter for Relfydess — Botox Rival Faces Regulatory Hurdle Regulatory

Galderma Receives Complete Response Letter for Relfydess — Botox Rival Faces Regulatory Hurdle

FDA rejects Galderma's new neuromodulator formulation; shares slide on failed market-entry bid.

Jul 4, 2026
Free alerts

Free: recall & rule-change alerts for your practice.

Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.

The free Inside MedSpa brief · no card · unsubscribe anytime. Privacy.

Inside MedSpa · Free brief

By the time it's news, it's too late.

FDA decisions, recalls and the rules you operate under, drafted from the source documents and sent free by email.

Get the free brief The free Inside MedSpa brief · no card · unsubscribe anytime.
FDA, recalls and rule changes for practice owners Get the free brief →